About this trial
The aim of these study to determine the prevalence of hepatitis Delta virus (HDV) infections and the prognosis of HDV patients in Turkey's southeast. The investigators intend to arrange training sessions for 250 family physicians in Diyarbakir, Batman, Mardin, and Sanliurfa in order to determine those goals. The investigators will talk about diagnosing hepatitis B virus (HBV), HDV, hepatitis C virus (HCV), and Human Immunodeficiency virus (HIV) infections during these events. To ensure that patients with simultaneous HDV infection are evaluated for HIV/HCV and to detect liver fibrosis with a non-invasive method.
Eligibility criteria
Qualifiers
Adults (Age≥18)
Being HBsAg positive for at least six months
Being a citizen of the Republic of Türkiye
Disqualifiers
There are no exclusion criteria in this study.
Trial design
Treatments tested in this trial
- Anti Delta
Treatment groups
Sponsors and collaborators
Yaşar Bayındır, MD
Lead sponsor
Guven Health Group
Sponsor institution
SOUTHEAST NEUROLOGY AND INFECTIOUS DISEASES SOCIETY
Collaborator
Gilead Sciences
Collaborator